A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis

Journal of Alzheimer's Disease

Volumn 47, Issue 1, 2015, Pages 33-47

  Atwood, Craig S ^a,b,c   Bowen, Richard L ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c EDITH COWAN UNIVERSITY   (Australia)

^d Pharmaceutical Res Network LLC   (Greece)

Author keywords

Alzheimer's disease; Amyloid protein precursor; Cell cycle re entry; Endocrine dyscrasia; Hypothalamic pituitarygonadal axis; Luteinizing hormone; Menopause; Neuron presenilin; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; NOTCH RECEPTOR; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; CELL CYCLE; CELL DIVISION; GENE MUTATION; HUMAN; LYMPHOCYTE; MITOGENESIS; MITOSIS; NERVE CELL; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; COMPLICATION; GENETICS; MEMORY DISORDERS; MUTATION; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CELL CYCLE; HUMANS; MEMORY DISORDERS; MUTATION; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; PRESENILIN-1;

EID: 84940914532     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143210     Document Type: Article

References (188)

1. Cotter VT (2007) The burden of dementia. Am J Manag Care 13(Suppl 8), S193-S197.
2. Alzheimer's Association. (2007) Alzheimer's Disease Facts and Figures 2007, http://www.alz.org/national/documents/ Report 2007FactsAndFigures.pdf
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
4. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: Back to the future. Neuron 68, 270-281.
5. Bird TD (1993) Early-onset familial Alzheimer disease. In GeneReviews(R), Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, eds., Seattle.
6. Seltzer B, Sherwin I (1983) A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two? Arch Neurol 40, 143-146.
7. Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76, 1720-1725.
8. Nochlin D, van Belle G, Bird TD, SumiSM(1993) Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord 7, 212-222.
9. Yasuno F, Imamura T, Hirono N, Ishii K, Sasaki M, Ikejiri Y, Hashimoto M, Shimomura T, Yamashita H, Mori E (1998) Age at onset and regional cerebral glucose metabolism in Alzheimer's disease. Dement Geriatr Cogn Dis 9, 63-67.
10. Bialopiotrowicz E, Szybinska A, Kuzniewska B, Buizza L, Uberti D, Kuznicki J, Wojda U (2012) Highly pathogenic Alzheimer's disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes. J Alzheimers Dis 32, 397-415.
11. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL (2003) DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 23, 6914-6927.
12. Atwood CS, Meethal SV, Liu T, Wilson AC, Gallego M, Smith MA, Bowen RL (2005) Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J Neuropathol Exp Neurol 64, 93-103.
13. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA (2000) Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 61, 128-133.
14. Herrup K, Neve R, Ackerman SL, Copani A (2004) Divide and die: Cell cycle events as triggers of nerve cell death. J Neurosci 24, 9232-9239.
15. Wang W, Bu B, Xie M, Zhang M,Yu Z, TaoD(2009) Neural cell cycle dysregulation and central nervous system diseases. Prog Neurobiol 89, 1-17.
16. Lee HG, Casadesus G, Zhu X, Castellani RJ, McShea A, Perry G, Petersen RB, Bajic V, Smith MA (2009) Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int 54, 84-88.
17. Neve RL, McPhie DL (2007) Dysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosis. Biochim Biophys Acta 1772, 430-437.
18. Mak GK, Enwere EK, Gregg C, Pakarainen T, Poutanen M, Huhtaniemi I, Weiss S (2007) Male pheromone-stimulated neurogenesis in the adult female brain: Possible role in mating behavior. Nat Neurosci 10, 1003-1011.
19. Hawken PA, Jorre TJ, Rodger J, Esmaili T, Blache D, Martin GB (2009) Rapid induction of cell proliferation in the adult female ungulate brain (Ovis aries) associated with activation of the reproductive axis by exposure to unfamiliar males. Biol Reprod 80, 1146-1151.
20. Smith CJ, Anderton BH, Davis DR, Gallo JM (1995) Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. FEBS Lett 375, 243-248.
21. Vincent TS, Hazen-Martin DJ, Garvin AJ (1996) Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett 103, 49-56.
22. Yang Y, Geldmacher DS, Herrup K (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21, 2661-2668.
23. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
24. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
25. Goedert M, Jakes R, Crowther RA, Six J, Lubke U, Vandermeeren M, Cras P, Trojanowski JQ, Lee VM (1993) The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A 90, 5066-5070.
26. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-betainduced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclindependent kinase 5 expression. J Neurochem 88, 554-563.
27. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX (2001) EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169, 27-32.
28. Carvalho CR, Carvalheira JB, Lima MH, Zimmerman SF, Caperuto LC, Amanso A, Gasparetti AL, Meneghetti V, Zimmerman LF, Velloso LA, Saad MJ (2003) Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: Activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144, 638-647.
29. Rubinfeld H, Seger R (2004) The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol Biol 250, 1-28.
30. Zhu X, Raina AK, Boux H, Simmons ZL, Takeda A, Smith MA (2000) Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int J Dev Neurosci 18, 433-437.
31. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X (2010) Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease? Mol Neurobiol 41, 87-96.
32. Bonda DJ, Evans TA, Santocanale C, Llosa JC, Vina J, Bajic VP, Castellani RJ, Siedlak SL, Perry G, Smith MA,Lee HG (2009) Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging 1, 382-388.
33. Thakur A, Siedlak SL, James SL, Bonda DJ, Rao A,Webber KM, Camins A, Pallas M, Casadesus G, Lee HG, Bowser R, Raina AK, Perry G, Smith MA, Zhu X (2008) Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol 1, 134-146.
34. Granic A, Padmanabhan J, Norden M, Potter H (2010) Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21; requirement for tau and APP. Mol Biol Cell 21, 511-520.
35. Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H (2008) Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging 29, 319-328.
36. Geller LN, Potter H (1999) Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiol Dis 6, 167-179.
37. Arendt T (2002) Dysregulation of neuronal differentiation and cell cycle control in Alzheimer's disease. J Neural Transm Suppl, 77-85.
38. Bowser R, Smith MA (2002) Cell cycle proteins in Alzheimer's disease: Plenty of wheels but no cycle. J Alzheimers Dis 4, 249-254.
39. Bonda DJ, Bajic VP, Spremo-Potparevic B, Casadesus G, Zhu X, Smith MA,LeeHG(2010) Cell cycle aberrations and neurodegeneration: A review. Neuropathol Appl Neurobiol 36, 157-163.
40. Varvel NH, Bhaskar K, Patil AR, Pimplikar SW, Herrup K, LambBT(2008) Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci 28, 10786-10793.
41. Nagy Z (2007) The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease. Biochim Biophys Acta 1772, 402-408.
42. Yang Y, Mufson EJ, Herrup K (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23, 2557-2563.
43. Busser J, Geldmacher DS, Herrup K (1998) Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18, 2801-2807.
44. Vincent I, Zheng JH, Dickson DW, Kress Y, Davies P (1998) Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging 19, 287-296.
45. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL (1993) Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann N Y Acad Sci 695, 91-102.
46. Larkins BA, Dilkes BP, Dante RA, Coelho CM, Woo YM, Liu Y (2001) Investigating the hows and whys of DNA endoreduplication. J Exp Bot 52, 183-192.
47. Olmo E (1983) Nucleotype and cell size in vertebrates: A review. Basic Appl Histochem 27, 227-256.
48. Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC (2007) Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 28, 1484-1492.
49. Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC (2008) Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 67, 578-589.
50. Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, Troncoso JC (2009) The Nun study: Clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73, 665-673.
51. O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC (2009) Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18, 665-675.
52. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210.
53. Vadakkadath Meethal S, Atwood CS (2005) The role of hypothalamic-pituitary-gonadal hormones in the normal structure and functioning of the brain. Cell Mol Life Sci 62, 257-270.
54. Park KH, Hallows JL, Chakrabarty P, Davies P, Vincent I (2007) Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J Neurosci 27, 2969-2978.
55. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, Linford NJ, Funk JO, Shapiro RA, Smith MA (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772, 467-472.
56. Takashima S, Kuruta H, Mito T, Nishizawa M, Kunishita T, Tabira T (1990) Developmental and aging changes in the expression patterns of beta-amyloid in the brains of normal and Down syndrome cases. Brain Dev 12, 367-371.
57. Berezovska O, Xia MQ, Page K, Wasco W, Tanzi RE, Hyman BT (1997) Developmental regulation of presenilin mRNAexpression parallels notch expression. J Neuropathol Exp Neurol 56, 40-44.
58. Glotzer M (1997) The mechanism and control of cytokinesis. Curr Opin Cell Biol 9, 815-823.
59. Chan GK, Yen TJ (2003) The mitotic checkpoint: A signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit. Prog Cell Cycle Res 5, 431-439.
60. Akers KG, Martinez-Canabal A, Restivo L, Yiu AP, De Cristofaro A, Hsiang HL, Wheeler AL, Guskjolen A, Niibori Y, Shoji H, Ohira K, Richards BA, Miyakawa T, Josselyn SA, Frankland PW (2014) Hippocampal neurogenesis regulates forgetting during adulthood and infancy. Science 344, 598-602.
61. Porayette P, Gallego MJ, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS (2009) Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 284, 23806-23817.
62. Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS (2007) Amyloid-beta precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 364, 522-527.
63. Freude KK, Penjwini M, Davis JL, LaFerla FM, Blurton- Jones M (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem 286, 24264-24274.
64. Citron M,WestawayD, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67-72.
65. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL (2003) DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 23, 6914-6927.
66. Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, Roberson ED, Bloom GS (2013) Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci 126, 1278-1286.
67. McPhie DL, Golde T, Eckman CB, Yager D, Brant JB, Neve RL (2001) beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. Brain Res Mol Brain Res 97, 103-113.
68. Yamatsuji T, Matsui T, Okamoto T, Komatsuzaki K, Takeda S, Fukumoto H, Iwatsubo T, Suzuki N, Asami- Odaka A, Ireland S, Kinane TB, Giambarella U, Nishimoto I (1996) G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 272, 1349-1352.
69. Yamatsuji T, Okamoto T, Takeda S, Murayama Y, Tanaka N, Nishimoto I (1996) Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. EMBO J 15, 498-509.
70. Ahn KW, Joo Y, Choi Y, Kim M, Lee SH, Cha SH, Suh YH, Kim HS (2008) Swedish amyloid precursor protein mutation increases cell cycle-related proteins in vitro and in vivo. J Neurosci Res 86, 2476-2487.
71. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713.
72. Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH (1999) Presenilin 1 facilitates the constitutive turnover of beta-catenin: Differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J Neurosci 19, 4229-4237.
73. Soriano S, Kang DE, Fu M, Pestell R, Chevallier N, Zheng H, Koo EH (2001) Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol 152, 785-794.
74. Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH(2005) Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol 167, 151-159.
75. Veeraraghavalu K, Choi SH, Zhang X, Sisodia SS. Presenilin 1 mutants impair the self-renewal and differentiation of adult murine subventricular zone-neuronal progenitors via cell-autonomous mechanisms involving notch signaling. J Neurosci 30, 6903-6915.
76. Malik B, Currais A, Andres A, Towlson C, Pitsi D, Nunes A, Niblock M, Cooper J, Hortobagyi T, Soriano S (2008) Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-1 Alzheimer's disease brain. Cell Cycle 7, 637-646.
77. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH,Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
78. Janicki SM, Monteiro MJ (1999) Presenilin overexpression arrests cells in the G1 phase of the cell cycle. Arrest potentiated by the Alzheimer's disease PS2(N141I)mutant. Am J Pathol 155, 135-144.
79. Janicki SM, Stabler SM, Monteiro MJ (2000) Familial Alzheimer's disease presenilin-1 mutants potentiate cell cycle arrest. Neurobiol Aging 21, 829-836.
80. de las Cuevas N, Urcelay E, Hermida OG, Saiz-Diaz RA, Bermejo F, Ayuso MS, Martin-Requero A (2003) Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol Dis 13, 254-263.
81. Bialopiotrowicz E, Kuzniewska B, Kachamakova- Trojanowska N, Barcikowska M, Kuznicki J, Wojda U (2011) Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer's disease patients. Neurobiol Aging 32, 2319 e2313-2326.
82. Tan M, Wang S, Song J, Jia J (2012) Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neurosci Lett 516, 226-231.
83. Zhou X, Jia J (2010) P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci Lett 468, 320-325.
84. Lanni C,RacchiM,UbertiD,MazziniG,StangaS, Sinforiani E, Memo M, Govoni S (2008) Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: Focus on p53. Curr Pharm Design 14, 2665-2671.
85. Porayette P, Gallego MJ, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS (2009) Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 284, 23806-23817.
86. Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS (2007) Amyloid-beta precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 364, 522-527.
87. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 23, 5531-5535.
88. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA (2004) Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A 101, 13363-13367.
89. Lopez-Toledano MA, Shelanski ML (2004) Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 24, 5439-5444.
90. Calafiore M, Battaglia G, Zappala A, Trovato-Salinaro E, Caraci F, Caruso M, Vancheri C, Sortino MA, Nicoletti F, CopaniA(2006) Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid. Neurobiol Aging 27, 606-613.
91. Heo C, Chang KA, Choi HS, Kim HS, Kim S, Liew H, Kim JA, Yu E, Ma J, Suh YH (2007) Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. J Neurochem 102, 493-500.
92. Sotthibundhu A, Li QX, Thangnipon W, Coulson EJ (2009) Abeta(1-42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. Neurobiol Aging 30, 1975-1985.
93. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164, 975-985.
94. Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ (2006) Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 495, 70-83.
95. Gan L, Qiao S, Lan X, Chi L, Luo C, Lien L, Yan Liu Q, Liu R (2008) Neurogenic responses to amyloid-beta plaques in the brain of Alzheimer's disease-like transgenic (pPDGFAPPSw, Ind) mice. Neurobiol Dis 29, 71-80.
96. Lopez-Toledano MA, Shelanski ML (2007) Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind). J Alzheimers Dis 12, 229-240.
97. Ermini FV, Grathwohl S, Radde R, Yamaguchi M, Staufenbiel M, Palmer TD, Jucker M (2008) Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. Am J Pathol 172, 1520-1528.
98. Atwood CS, Meethal SV, Liu T, Wilson AC, Gallego M, Smith MA, Bowen RL (2005) Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J Neuropathol Exp Neurol 64, 93-103.
99. Cole LA (2009) Human chorionic gonadotropin and associated molecules. Exp Rev Mol Diagn 9, 51-73.
100. Cole LA (2012) HCG variants, the growth factors which drive human malignancies. Am J Cancer Res 2, 22-35.
101. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279, 20539-20545.
102. Saberi S, Du YP, Christie M, Goldsbury C (2013) Human chorionic gonadotropin increases beta-cleavage of amyloid precursor protein in SH-SY5Y cells. Cell Mol Neurobiol 33, 747-751.
103. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4, 447-451.
104. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B,Wang R, Greengard P (2000) Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A 97, 1202-1205.
105. Pike CJ, Carroll JC, Rosario ER, BarronAM(2009) Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 30, 239-258.
106. Berry A, Tomidokoro Y, Ghiso J, Thornton J (2008) Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm Behav 54, 143-152.
107. Wahjoepramono EJ, Wijaya LK, Taddei K, Bates KA, Howard M, Martins G, deRuyck K, Matthews PM, Verdile G, Martins RN (2011) Direct exposure of guinea pig CNS to human luteinizing hormone increases cerebrospinal fluid and cerebral beta amyloid levels. Neuroendocrinology 94, 313-322.
108. Lin J, Li X, Yuan F, Lin L, Cook CL, Rao Ch V, Lei Z (2010) Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 69, 253-261.
109. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E,Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
110. Yang Y, Mufson EJ, Herrup K (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neuosci 23, 2557-2563.
111. Verdile G, Yeap BB, Clarnette RM, Dhaliwal S, Burkhardt MS, Chubb SA, De Ruyck K, Rodrigues M, Mehta PD, Foster JK, Bruce DG, Martins RN (2008) Luteinizing hormone levels are positively correlated with plasma amyloid-beta protein levels in elderly men. J Alzheimers Dis 14, 201-208.
112. Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K,Villemagne VL, MartinsRN (2014) Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer's disease. Mol Psychiatry 19, 69-75.
113. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B (2012) Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev 64, 1004-1026.
114. Clark IA, Atwood CS (2011) Is TNF a link between agingrelated reproductive endocrine dyscrasia and Alzheimer's disease? J Alzheimers Dis 27, 691-699.
115. Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ (1984) Cell cycle-specific effects of tumor necrosis factor. Cancer Res 44, 83-90.
116. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C (2013) Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 27, 153-156.
117. Casadesus G, Webber KM, Atwood CS, Bowen RL, Perry G, Smith MA (2006) Luteinizing hormone mediates Alzheimer-type changes in neurons. Alzheimers Dement 2(Suppl), S462.
118. Brion JP, Couck AM (1995) Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 147, 1465-1476.
119. Brion JP, Octave JN, Couck AM (1994) Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience 63, 895-909.
120. Kanemaru K, Takio K, Miura R, Titani K, Ihara Y (1992) Fetal-type phosphorylation of the tau in paired helical filaments. J Neurochem 58, 1667-1675.
121. Pope WB, Lambert MP, Leypold B, Seupaul R, Sletten L, Krafft G, Klein WL (1994) Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. Exp Neurol 126, 185-194.
122. Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK (1995) Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease. Neuroscience 68, 5-18.
123. Arendt T, Rodel L, Gartner U, Holzer M (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 7, 3047-3049.
124. Vincent I, Rosado M, Davies P (1996) Mitotic mechanisms in Alzheimer's disease? J Cell Biol 132, 413-425.
125. Nagy Z, Esiri MM, Cato AM, Smith AD (1997) Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol 94, 6-15.
126. Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR (2004) Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 6, 659-671; discussion 673-681.
127. Leugers CJ, Koh JY, Hong W, Lee G (2013) Tau in MAPK activation. Front Neurol 4, 161.
128. Leugers CJ, Lee G (2010) Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem 285, 19125-19134.
129. Musa FR, Takenaka I, Konishi R, Tokuda M (2000) Effects of luteinizing hormone, follicle-stimulating hormone, and epidermal growth factor on expression and kinase activity of cyclin-dependent kinase 5 in Leydig TM3 and Sertoli TM4 cell lines. J Androl 21, 392-402.
130. Cicero S, Herrup K (2005) Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci 25, 9658-9668.
131. Zhang J, Herrup K (2008) Cdk5 and the non-catalytic arrest of the neuronal cell cycle. Cell Cycle 7, 3487-3490.
132. Nikolic M, Dudek H, Kwon YT, Ramos YF, Tsai LH (1996) The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 10, 816-825.
133. Zhang J, Herrup K (2011) Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in post-mitotic neurons. Cell Cycle 10, 1208-1214.
134. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K (2010) Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 30, 5219-5228.
135. Zhang J, Li H, Herrup K (2010) Cdk5 nuclear localization is p27-dependent in nerve cells: Implications for cell cycle suppression and caspase-3 activation. J Biol Chem 285, 14052-14061.
136. O'Hare MJ, Kushwaha N, Zhang Y, Aleyasin H, Callaghan SM, Slack RS, Albert PR, Vincent I, Park DS (2005) Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 25, 8954-8966.
137. Zhang J, Li H, Herrup K Cdk5 nuclear localization is p27-dependent in nerve cells: Implications for cell cycle suppression and caspase-3 activation. J Biol Chem 285, 14052-14061.
138. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K. Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 30, 5219-5228.
139. Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J (2014) CDK5 activator protein p25 preferentially binds and activates GSK3beta. Proc Natl Acad Sci U S A 111, E4887-E4895.
140. Flynn MP, Maizels ET, Karlsson AB, McAvoy T, Ahn JH, Nairn AC, Hunzicker-Dunn M (2008) Luteinizing hormone receptor activation in ovarian granulosa cells promotes protein kinase A-dependent dephosphorylation of microtubule-associated protein 2D. Mol Endocrinol 22, 1695-1710.
141. Hoerndli FJ, Pelech S, Papassotiropoulos A, Gotz J (2007) Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. Eur J Neurosci 26, 60-72.
142. Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: Implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27, 943-957.
143. Lopes JP, Oliveira CR, Agostinho P (2009) Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell Cycle 8, 97-104.
144. Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: Implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27, 943-957.
145. Lopes JP, Oliveira CR, Agostinho P. Neurodegeneration in an Abeta-induced model of Alzheimer's disease: The role of Cdk5. Aging Cell 9, 64-77.
146. Lopes JP, Blurton-Jones M, Yamasaki TR, Agostinho P, LaFerlaFM(2009) Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis 16, 541-549.
147. Kuhla A, Ludwig SC, Kuhla B, Munch G, Vollmar B (2015) Advanced glycation end products are mitogenic signals and trigger cell cycle re-entry of neurons in Alzheimer's disease brain. Neurobiol Aging 36, 753-761.
148. Diamanti-Kandarakis E, Lambrinoudaki I, Economou F, Christou M, Piperi C, Papavassiliou AG, Creatsas G (2010) Androgens associated with advanced glycation end-products in postmenopausal women. Menopause 17, 1182-1187.
149. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G (2005) Increased levels of serum advanced glycation endproducts in women with polycystic ovary syndrome. Clin Endocrinol 62, 37-43.
150. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ,WascoW, Da Silva HA, Haines JL, Perkicak-VanceMA,Tanzi RE, Roses AD,Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
151. Levy-Lahad E,WascoW, Poorkaj P, Romano DM,Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
152. Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W,Wehnert A, Vegter-Van der Vlis M, Roos RA (1990) Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 248, 1120-1122.
153. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, FrangioneB( 1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126.
154. Lannfelt L, Bogdanovic N, Appelgren H, Axelman K, Lilius L, Hansson G, Schenk D, Hardy J, Winblad B (1994) Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci Lett 168, 254-256.
155. Sherwin BB, Tulandi T (1996) "Add-back" estrogen reverses cognitive deficits induced by a gonadotropinreleasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81, 2545-2549.
156. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ, 3rd (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69, 1074-1083.
157. Gleason CE, Cholerton B, Carlsson CM, Johnson SC, Asthana S (2005) Neuroprotective effects of female sex steroids in humans: Current controversies and future directions. Cell Mol Life Sci 62, 299-312.
158. Jorm AF, Korten AE, Henderson AS (1987) The prevalence of dementia:Aquantitative integration of the literature. Acta Psychiatr Scand 76, 465-479.
159. McGonigal G, Thomas B, McQuade C, Starr JM, MacLennan WJ, Whalley LJ (1993) Epidemiology of Alzheimer's presenile dementia in Scotland, 1974-88.BMJ306, 680-683.
160. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
161. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 55, 809-815.
162. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, HofmanA(1999) Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53, 1992-1997.
163. Hy LX, Keller DM (2000) Prevalence of AD among whites: A summary by levels of severity. Neurology 55, 198-204.
164. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R (2000) Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54, 833-837.
165. Bowen RL, Isley JP, Atkinson RL (2000) An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 12, 351-354.
166. Hogervorst E, Bandelow S, Combrinck M, SmithAD(2004) Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 39, 1633-1639.
167. Short RA, Bowen RL, O'Brien PC, Graff-Radford NR (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76, 906-909.
168. Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, SmithAD(2001) Serum total testosterone is lower in men with Alzheimer's disease. Neuroendocrinol Lett 22, 163-168.
169. Hogervorst E, Combrinck M, Smith AD (2003) Testosterone and gonadotropin levels in men with dementia. Neuro Endocrinol Lett 24, 203-208.
170. Rodrigues MA, Verdile G, Foster JK, Hogervorst E, Joesbury K, Dhaliwal S, Corder EH, Laws SM, Hone E, Prince R, Devine A, Mehta P, Beilby J, Atwood CS, Martins RN (2008) Gonadotropins and cognition in older women. J Alzheimers Dis 13, 267-274.
171. Hyde Z, Flicker L, Almeida OP, McCaul KA, Jamrozik K, Hankey GJ, Chubb SA, Yeap BB (2010) Higher luteinizing hormone is associated with poor memory recall: The health in men study. J Alzheimers Dis 19, 943-951.
172. D'AmicoAV, Braccioforte MH,Moran BJ, ChenMH(2010) Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord 24, 85-89.
173. Bowen RL, Beaird H, Atwood CS, Smith MA, Rimm AA (2004) Late Breaking Abstract: Men treated for prostate cancer have a decreased incidence of dementia. 9th International Conference on Alzheimer's Disease and Related Disorders, 17-22 July 2004, Philadelphia, PA, USA.
174. Nedelec C, Ragot S, Irani J, Pires C, Gil R, Dore B (2009) Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate. Prog Urol 19, 47-53.
175. Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS (2015) A clinical study of lupron depot in the treatment of women with Alzheimer's disease: Preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis 44, 549-560.
176. Bowen RL, Atwood CS (2004) Living and dying for sex. A theory of aging based on the modulation of cell cycle signaling by reproductive hormones. Gerontology 50, 265-290.
177. Yang Y, Herrup K (2005) Loss of neuronal cell cycle control in ataxia-telangiectasia: A unified disease mechanism. J Neurosci 25, 2522-2529.
178. Atwood CS, Barzilai N, Bowen RL, Brown-Borg HM, Jarrard DF, Fu VX, Heilbronn LK, Ingram DK, Ravussin E, Schwartz RS, Weindruch R (2003) Pennington scientific symposium on mechanisms and retardation of aging. Exp Gerontol 38, 1217-1226.
179. Tan RS, Pu SJ (2003) A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 6, 13-17.
180. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S (2005) Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64, 2063-2068.
181. Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR (1999) Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 24, 657-677.
182. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR (2001) High-dose estradiol improves cognition for women with AD: Results of a randomized study. Neurology 57, 605-612.
183. Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S (2011) Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausalwomen with Alzheimer's disease: Results of a randomized controlled trial. J Alzheimers Dis 26, 495-505.
184. Atwood C, Bowen R (2015) The endocrine dyscrasia that accompanies menopause and andropause induces aberrant cell cycle signaling that triggers cell cycle re-entry of postmitotic neurons, neurodegeneration and cognitive disease Horm Behav, in press.
185. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA (2013) Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340, 924-g.
186. Cramer PE, Cirrito JR,Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
187. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle re-entry in a mouse model of Alzheimer disease. J Clin Invest 119, 3692-3702.
188. Atwood C (2010) Amyloid- aggregation as a protective acute-phase response to injury/neurodegeneration: A barrier function for amyloid- deposits. In Functional Amyloid Aggregation, Rigacci S, Bucciantini M, eds. Research Signpost, Kerala, India, pp. 115-134.